Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy Neoadjuvante Chemotherapie mit Cabazitaxel vor der radikalen Prostatektomie
Phase of Trial: Phase II
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CLUBNET-CABAZ
- Sponsors Sanofi
- 12 Sep 2016 Status changed from suspended to discontinued as the investigator left the site
- 15 Sep 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 12 Sep 2013 Planned end date changed from 12 Jun 2015 to 1 Aug 2018, as reported by ClinicalTrials.gov.